TMS vs. Ketamine: What TRD Patients Should Know

Ketamine and TMS Are Getting More Attention for Hard-to-Treat Depression

A new piece from Medical Daily is drawing attention to two of the most discussed interventions for treatment-resistant depression (TRD): transcranial magnetic stimulation (TMS) and ketamine. For the estimated 30% of people with major depressive disorder who don't respond adequately to two or more antidepressants, these treatments represent a meaningful fork in the road — and the question of which to try, and when, matters more than ever.

The article outlines a practical framework: TMS is a non-pharmacological option that uses magnetic pulses to stimulate nerve cells in regions of the brain linked to mood regulation. It requires multiple in-office sessions over several weeks and is FDA-cleared for depression. Ketamine works through a fundamentally different mechanism — blocking NMDA receptors and triggering rapid glutamate signaling — often producing noticeable relief within hours rather than weeks. That speed of action is one of ketamine's defining clinical advantages, especially for patients in acute distress.

For TRD patients, both carry real promise. But they differ substantially in how they're delivered, what the experience feels like, how long effects last, and — critically — how accessible they are depending on your location, insurance situation, and provider network. Understanding those differences helps patients ask better questions and build a more realistic treatment plan.

Where Ketamine Troches Fit in the Picture

The Medical Daily article focuses primarily on IV infusions and Spravato nasal spray as the ketamine formats patients are likely to encounter in clinical settings. But for many people navigating TRD in 2026, ketamine troches — sublingual lozenges containing compounded ketamine — have become an increasingly common entry point, particularly through telehealth-based treatment programs.

Troches occupy a distinct position in the ketamine treatment spectrum. Unlike IV infusions, which require a clinic visit, monitoring equipment, and often a steep per-session fee, troches can be prescribed through a licensed provider and dispensed by a compounding pharmacy for at-home use. Unlike Spravato, which must be administered in a certified healthcare setting with a mandatory post-dose observation period, troches are taken independently — held sublingually for 15 to 20 minutes — and can fit into a patient's own space and schedule.

This practical flexibility matters for TRD patients. Troches typically produce a milder dissociative experience than IV ketamine and are generally dosed lower, making them a viable option for patients who want to maintain a regular treatment rhythm without repeated clinic visits. In clinical practice, they're often used for maintenance — a patient might complete an IV induction series and then transition to troches for ongoing support, or start with troches as a first ketamine exposure under medical supervision.

Compounding is central to how troches work. Because standard oral ketamine tablets aren't commercially manufactured for psychiatric use in the U.S., licensed compounding pharmacies formulate troches to a provider's specifications — allowing customization of dose, concentration, and even flavor. This flexibility is genuinely useful, but it also means patients need to work with providers who understand compounding pharmacy relationships and can adjust formulations as treatment evolves over time.

Understanding the Timeline and What to Expect

One of the most useful things mainstream coverage like this highlights is patient expectations around timing — and this is an area where troches differ meaningfully from infusions. IV ketamine can produce significant mood shifts after just one to three sessions, sometimes within 24 hours of the first infusion. Troches typically act on a longer arc. Most protocols involve multiple sessions per week over several weeks, with effects building cumulatively rather than arriving all at once.

That's not a drawback — it's a different clinical profile suited to different patients. Troches work well for people who prefer gradual titration, those who found IV ketamine's intensity disorienting, or those integrating ketamine into a broader care plan that includes psychotherapy. Many troche protocols are specifically designed to pair with therapy sessions, leveraging the neuroplasticity window ketamine opens to support deeper therapeutic engagement.

Safety guardrails differ by format, too. IV settings come with direct medical supervision throughout the session. Troche protocols place more responsibility on the patient at home, which means good provider selection, clear preparation guidance, and strong communication channels between patient and prescriber are essential. Reputable programs build in preparation materials, integration support, and structured check-ins — and patients should expect those components, not treat them as optional add-ons.

What This Means for Patients Considering Troches

Coverage like this in mainstream health media helps normalize the conversation around ketamine for TRD — which benefits patients who've struggled for years without relief and may have dismissed ketamine as too intense or too experimental. As reporting increasingly reflects, ketamine is part of the standard clinical conversation around hard-to-treat depression in 2026, not a fringe last resort.

For patients who've read this kind of coverage and are now curious about troches specifically, a few practical points are worth keeping in mind:

Troches require a real clinical relationship. A prescriber should take a thorough history, screen for contraindications — uncontrolled hypertension, active psychosis, certain cardiac conditions — and monitor progress over time. Be cautious of any program that rushes the intake process or doesn't offer ongoing clinical oversight.

Compounding quality matters. Not all compounding pharmacies operate at the same standard. Providers who work with PCAB-accredited pharmacies or can clearly explain their quality assurance process offer better accountability than those who can't answer basic questions about their dispensing partners.

Insurance coverage remains inconsistent. Spravato has an FDA indication and may be covered in some circumstances. Compounded troches are typically out-of-pocket. Understanding total program costs — not just the prescription price but the full multi-month protocol — is an important part of planning before you begin.

Troches and TMS aren't mutually exclusive. Some patients pursue both, either concurrently or in sequence. Partial response to one doesn't rule out benefit from the other, and troche maintenance alongside other therapeutic modalities is a legitimate long-term strategy for some patients.

The broader takeaway from the Medical Daily piece is that TRD patients now have more clinically validated options than at any previous point, and the medical community is getting better at helping people navigate between them. Ketamine troches are a meaningful part of that landscape — not as a compromise between infusions and nothing, but as a genuinely useful tool for the right patient at the right point in their treatment journey.